At the Astana International Financial Centre (AIFC), the next acceleration meeting was held to identify systemic problems and barriers hindering the implementation of investment projects in Kazakhstan’s pharmaceutical and healthcare sectors.

The event, organized by JSC NC “KAZAKH INVEST,” was attended by Deputy Minister of Foreign Affairs Nazira Nurbayeva, Vice Minister of Healthcare of the Republic of Kazakhstan Zhandos Burkitbayev, as well as representatives of government bodies and medical companies, including JSC National Holding “QazBioPharm,” LLP “SK-Pharmacy,” JSC “Turar Healthcare,” LLP “Dolce Pharm,” LLP “Roche Kazakhstan,” “Pfizer Export B.V.,” JSC “Ordamed,” “Orhun Medical,” and others.

Opening the meeting, Deputy Minister of Foreign Affairs Nazira Nurbayeva emphasized that the healthcare and pharmaceutical sectors have significant potential and are priority areas, given the Head of State’s directive to increase the share of domestic pharmaceutical production in the country to 50%. According to her, the country is experiencing growing demand for medicines, and improving current regulatory standards will contribute to modernizing the sectors and attracting new investments.

During the event, participants raised a number of pressing issues, including the long time (5–7 years) for innovative medicines to enter the market, problems with drug pricing regulation, frequent changes in legislation, imperfections in patent protection laws, as well as logistical challenges.